The proline-rich domain in p63 is necessary for the transcriptional and apoptosis-inducing activities of TAp63

Oncogene

Volumn 27, Issue 20, 2008, Pages 2843-2850

  Helton, E S ^a   Zhang, J ^a   Chen, X ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cell cycle; p53 family; p63; Transcription

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; ISOPROTEIN; ONCOPROTEIN; PROLINE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN P63; PROTEIN P63 ALPHA; PROTEIN P63 BETA; PROTEIN P63 GAMMA; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRON; ISOMERIZATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSACTIVATION; WILD TYPE;

AMINO ACID SEQUENCE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GROWTH INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; PROLINE; PROMOTER REGIONS (GENETICS); PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 42949117782     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210948     Document Type: Article

References (24)

1. Attardi LD, Donehower LA. (2005). Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res 576: 4-21.
2. Baptiste N, Friedlander P, Chen X, Prives C. (2002). The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21: 9-21.
3. Boyle JM, Greaves MJ, Roberts SA, Tricker K, Burt E, Varley JM et al. (1998). Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families. Br J Cancer 77: 2181-2192.
4. Brunner HG, Hamel BC, Bokhoven Hans van. (2002). P63 gene mutations and human developmental syndromes. Am J Med Genet 112: 284-290.
5. Chen C, Okayama H. (1987). High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7: 2745-2752.
6. Chen X, Ko LJ, Jayaraman L, Prives C. (1996). p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10: 2438-2451.
7. Dohn M, Zhang S, Chen X. (2001). p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20: 3193-3205.
8. Edwards SJ, Hananeia L, Eccles MR, Zhang YF, Braithwaite AW. (2003). The proline-rich region of mouse p53 influences transactivation and apoptosis but is largely dispensable for these functions. Oncogene 22: 4517-4523.
9. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J et al. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174.
10. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowley D et al. (2005). Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7: 363-373.
11. Ghioni P, Bolognese F, Duijf PHG, van Bokhoven H, Mantovani R, Guerrini L. (2002). Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 22: 8659-8668.
12. Gressner O, Schilling T, Lorenz K, Schleithoff ES, Koch A, Schulze-Bergkamen H et al. (2005). TAp63a induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J 24: 2458-2471.
13. Harms KL, Chen X. (2005). The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol 25: 2014-2030.
14. Helton ES, Zhu J, Chen X. (2006). The unique NH2-terminally deleted ({delta}N) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the {delta}N variant of p63. J Biol Chem 281: 2533-2542.
15. King KE, Ponnamperuma RM, Yamashita T, Tokino T, Lee LA, Young MF et al. (2003). DeltaNp63alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Oncogene 22: 3635-3644.
16. Liu G, Chen X. (2002). The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 21: 7195-7204.
17. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713.
18. Phang BH, Sabapathy K. (2007). The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models. Oncogene 26: 2964-2974.
19. Senoo M, Manis JP, Alt FW, McKeon F. (2004). p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell 6: 85-89.
20. Walker KK, Levine A. (1996). Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93: 15335-15340.
21. Willis A, Jung EJ, Wakefield T, Chen X. (2004). Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23: 2330-2338.
22. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2: 305-316.
23. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-718.
24. Zhu J, Jiang J, Zhou W, Zhu K, Chen X. (1999). Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18: 2149-2155.